Needham Investment Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Needham Investment Management’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,443,400	Closed	-$5.95M	–	119
2020 Q1	$5.95M	Buy	1,443,400 +648,400	+82%	+$3.04M	1.68%	17
2019 Q4	$3.82M	Buy	795,000 +545,000	+218%	+$3.01M	1.04%	32
2019 Q3	$1.51M	Buy	250,000 +60,000	+32%	+$374K	0.49%	45
2019 Q2	$1.23M	Sell	190,000 -50,500	-21%	-$356K	0.41%	51
2019 Q1	$1.71M	Sell	240,500 -40,000	-14%	-$263K	0.58%	42
2018 Q4	$1.36M	Buy	280,500 +20,500	+8%	+$107K	0.51%	43
2018 Q3	$1.91M	Buy	260,000 +30,000	+13%	+$220K	0.58%	47
2018 Q2	$1.47M	Buy	230,000 +50,000	+28%	+$330K	0.41%	53
2018 Q1	$979K	Hold	180,000	–	–	0.28%	58
2017 Q4	$750K	Buy	180,000 +123,000	+216%	+$740K	0.2%	68
2017 Q3	$550K	Buy	57,000 +7,000	+14%	+$72.7K	0.14%	77
2017 Q2	$592K	Buy	+50,000	New	+$639K	0.16%	75

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Needham Investment Management's GNMK Position: Q2 2020 in Review

Needham Investment Management sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 1,443,400 shares — an estimated $5.95M sold.

Needham Investment Management first reported a position in GNMK in Q2 2017 and held it in 12 quarters. The position peaked at $5.95M in Q1 2020. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

Needham Investment Management reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
Needham Investment Management sold 1,443,400 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $5.95M.
Needham Investment Management first reported a position in GenMark Diagnostics, Inc in Q2 2017 and held it in 12 quarters.
Needham Investment Management's GenMark Diagnostics, Inc position peaked at $5.95M in Q1 2020.
148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Needham Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.